If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Exercise of warrants

19 Aug 2025 07:00

RNS Number : 7865V
Aptamer Group PLC
19 August 2025
 

 

 

 

19 August 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Exercise of warrants

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, is pleased to announce that it has received notice to exercise warrants over a total of 36,000,000 new ordinary shares of £0.001 each in the Company ("Warrant Shares") at an exercise price of £0.002 per Warrant Share, raising £72,000 for the Company.

 

Total voting rights

An application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or around 22 August 2025.

 

Immediately following Admission, the Company will have 2,696,978,377 ordinary shares of £0.001 each in issue. The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

 

- Ends -

 

For further information, please contact: 

 

Aptamer Group plc

Dr Arron Tolley, Chief Executive Officer

+44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Jade Bayat

+44 (0) 20 3368 3550

Turner Pope Investments (TPI) Limited - Broker

James Pope / Andrew Thacker

+44 (0) 20 3657 0050

Northstar Communications Limited - Investor Relations

Sarah Hollins 

+44 (0) 113 730 3896

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

 

​Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGZGMRVRDGKZM

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS